SENSCIS 试验中系统性硬化症相关间质性肺病患者的循环生物标志物
本研究基于 SENSCIS 试验,评估系统性硬化症相关间质性肺病(SSc-ILD)患者循环蛋白的预后意义及尼达尼布对其影响。结果显示基线 KL-6>1000 U/mL 与 FVC 下降更快相关,尼达尼布降低 CA-125 和 pro-C6 水平。
要点
- 基线 KL-6>1000 U/mL 的 SSc-ILD 患者 52 周 FVC 下降更快。
- 尼达尼布较安慰剂降低 CA-125 和 pro-C6 水平。
- 尼达尼布对 FVC 变化的 48.0% 归因于 24 周 CA-125 下降。
核心结论
- 应用 KL-6 二分类阈值有助于识别 ILD 进展更快的 SSc-ILD 患者。
- 尼达尼布降低上皮功能障碍标志物 CA-125 和胶原合成表位 pro-C6 水平。
研究设计与样本
- SENSCIS 试验的事后分析,患者为 SSc 且距首次非雷诺症状≤7 年。
- 在血清/血浆中检测炎症、上皮功能障碍、ECM 合成及 ECM 转换的候选生物标志物。
主要发现
- 未校正分析中,基线 KL-6 和 MMP-2/8 降解瓜氨酸化波形蛋白(VICM)水平与 52 周 FVC 下降速率显著相关。
- 多重比较校正后,较高基线 Pro-C3、CCL2 和 CRP 水平与 52 周 mRSS 改善较少显著相关。
- 尼达尼布组较安慰剂组观察到 52 周 CA-125 和 pro-C6 下降。
- 中介分析中,尼达尼布对 52 周 FVC 变化的效应有 48.0% 归因于 24 周 CA-125 的治疗相关下降。
关键数值与推荐
- 基线 KL-6 阈值:>1000 vs ≤1000 U/mL。
临床怎么用
- KL-6 二分类阈值可用于识别 ILD 进展更快的 SSc-ILD 患者。
- 尼达尼布治疗与 CA-125 和 pro-C6 水平降低相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to determine the prognostic significance of circulating proteins and the effects of nintedanib on these proteins in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in the safety and efficacy of nintedanib in systemic sclerosis study (SENSCIS) trial. METHODS: Patients had SSc with ≤7 years since their first non-Raynaud symptom. Candidate biomarkers of inflammation, epithelial dysfunction, extracellular matrix (ECM) synthesis, and ECM turnover were measured in serum/plasma. We assessed associations between baseline biomarker levels and decline in forced vital capacity (FVC) over 52 weeks and change in modified Rodnan Skin Score (mRSS) at week 52 in the placebo group, and changes in biomarker levels in nintedanib and placebo groups. RESULTS: Baseline Krebs von den Lungen-6 (KL-6) and citrullinated vimentin (VICM) degraded by MMP-2/8 levels were significantly associated with the rate of decline in FVC over 52 weeks in uncorrected analyses. A baseline KL-6 concentration of >1000 vs ≤1000 U/mL was associated with a greater rate of decline in FVC (mL) over 52 weeks (estimates: -132.5 [95% CI: -174.1, -91.0] vs -56.4 [-95.2, -17.6]; P = .009). Higher baseline N-terminal propeptide of type III collagen (Pro-C3), chemokine (C-C motif) ligand 2, and C-reactive protein levels were significantly associated with less improvement in mRSS at week 52 in analyses corrected for multiple comparisons. Decreases in cancer antigen (CA)-125 and N-terminal propeptide of type VI collagen (pro-C6) over 52 weeks were observed in patients who received nintedanib vs placebo. In mediation analysis, 48.0% of the effect of nintedanib on change in FVC at week 52 was attributed to the treatment-related decrease in CA-125 at week 24. CONCLUSIONS: Applying a dichotomised threshold for KL-6 can aid in identifying patients with SSc-ILD with more progressive ILD. Nintedanib reduced levels of the epithelial dysfunction marker, CA-125, and collagen synthesis epitope, pro-C6.
引用
- Assassi S, Kuwana M, Denton CP, et al. Circulating biomarkers in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial. Ann Rheum Dis. 2026. PMID: 42532724. doi:10.1016/j.ard.2026.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。